Analytical Data
-
Gene name
FCRL4
- Application
-
Alternative Names
FCRL4；FCRH4；IFGP2；IRTA1；Fc receptor-like Protein 4
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96PJ5
-
Expression Region
20-387aa
-
AA Sequence
AHKPVISVHPPWTTFFKGERVTLTCNGFQFYATEKTTWYHRHYWGEKLTLTPGNTLEVRESGLYRCQARGSPRSNPVRLLFSSDSLILQAPYSVFEGDTLVLRCHRRRKEKLTAVKYTWNGNILSISNKSWDLLIPQASSNNNGNYRCIGYGDENDVFRSNFKIIKIQELFPHPELKATDSQPTEGNSVNLSCETQLPPERSDTPLHFNFFRDGEVILSDWSTYPELQLPTVWRENSGSYWCGAETVRGNIHKHSPSLQIHVQRIPVSGVLLETQPSGGQAVEGEMLVLVCSVAEGTGDTTFSWHREDMQESLGRKTQRSLRAELELPAIRQSHAGGYYCTADNSYGPVQSMVLNVTVRETPGNRDGL
-
Molecular Weight
43.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FCRL4, or Fc receptor-like 4, is a member of the FCRL family of proteins that play significant roles in immune regulation. Specifically, FCRL4 is expressed predominantly on B cells, particularly in conditions such as chronic inflammation and autoimmune diseases. Its expression is correlated with various pathological states, making it an attractive target for therapeutic intervention. Researchers have been increasingly interested in understanding the precise mechanisms through which FCRL4 influences immune responses, including its interactions with antibodies and other immune cell receptors. The study of recombinant FCRL4 proteins has gained momentum as it provides insights into the structural and functional aspects of this molecule. By investigating the binding affinities and signaling pathways associated with FCRL4, scientists aim to elucidate its role in modulating immune responses and its potential implications in diseases like systemic lupus erythematosus and rheumatoid arthritis. This research holds promise for developing novel strategies for immune modulation, targeting the pathways influenced by FCRL4 to improve therapeutic outcomes in various immune-related disorders.
